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Anastrozole-Induced Carpal Tunnel Syndrome: Results From
the International Breast Cancer Intervention Study II
Prevention Trial
Francesco Spagnolo, Ivana Sestak, Anthony Howell, John F. Forbes, and Jack Cuzick
A B S T R A C T
Purpose
Carpal tunnel syndrome (CTS) occurs when the median nerve is compressed at the wrist in the
carpal tunnel. It has been suggested that hormonal risk factors may be involved in the pathogenesis
of CTS, and a higher incidence of CTS has been reported in randomized clinical trials with aromatase
inhibitors (AIs) compared with tamoxifen.
Patients and Methods
This was an exploratory analysis of the International Breast Cancer Intervention Study II, a double-
blind randomized clinical trial in which women at increased risk of breast cancer were randomly
assigned to receive anastrozole or placebo. This is the ﬁrst report of risk factors for and charac-
teristics of CTS in women taking an AI in a placebo-controlled trial.
Results
Overall, 96 participants with CTS were observed: 65 (3.4%) in the anastrozole arm and 31 (1.6%) in
the placebo arm (odds ratio, 2.16 [1.40 to 3.33]; P, .001). Ten participants were reported as having
severe CTS, of which eight were taking anastrozole (P = .08). Eighteen women (0.9%) in the
anastrozole arm and six women (0.3%) in the placebo arm reported surgical intervention, which was
signiﬁcantly different (odds ratio, 3.06 [1.21 to 7.72], P = .018). Six women discontinued with the
allocated treatment because of the onset of CTS. Apart from treatment allocation, a high body mass
index and an a prior report of musculoskeletal symptoms after trial entry were the only other risk
factors for CTS identiﬁed in these postmenopausal women.
Conclusions
The use of anastrozole was associated with a higher incidence of CTS but few participants required
surgery. Further investigations are warranted into the risk factors and treatment of AI-induced CTS.
J Clin Oncol 34:139-143. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Carpal tunnel syndrome (CTS) occurs when the
median nerve, which runs from the forearm into
the hand, is compressed in the carpal tunnel, an
osteoﬁbrous, not extensible outlet at the wrist. It
is the most common entrapment neuropathy
and in most cases is idiopathic. Secondary
CTS may be caused by abnormalities of the shape
or position of the carpal bones surrounding the
tunnel (eg, acromegaly and osteoarthritis) or by
the contents of the tunnel (such as synovial
hypertrophy, intracanalicular tumors, inﬂam-
matory or metabolic tenosynovitis, or abnor-
mal ﬂuid distribution such as in pregnancy).1
Diagnosis of CTS is mainly clinical,1 with
nocturnal acroparaesthesia being the most sen-
sitive symptom.2 Paraesthesia in median nerve
territory is described as needles, burning sensa-
tion, tingling, heaviness, or electric impulses,
usually accompanied by pain radiating to the
forearm, elbow, or shoulder. Other symptoms
include a decrease in strength, morning edema,
and cold intolerance.1 Additional tests such as
nerve conduction studies are not essential for the
diagnosis of a typical form of CTS and do not
provide any additional evidence compared with
clinical assessment.3
It has been suggested that hormonal risk
factors may be involved in the pathogenesis of
CTS. Women have a three times–increased risk of
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developing CTS compared with men, especially around the time of
menopause.4,5 Pregnancy,6 bilateral oophorectomy,7 and use of
the combined oral contraceptive8 have all been identiﬁed as risk
factors for CTS. In contrast, menopausal hormone replacement
therapy (MHT) has been shown to lead to resolution of CTS in
menopausal women.9,10 Increased risk of CTS has also been reported
with third-generation aromatase inhibitors (AIs) anastrozole,11
exemestane,12 and letrozole,13 which have become established
adjuvant treatment of postmenopausal women with hormone
receptor–positive breast cancer, because they have been shown to
signiﬁcantly lower recurrence rates compared with tamoxifen.14
In addition, the International Breast Cancer Intervention Study
(IBIS)-II and Mammary Prevention (MAP) 3 trials showed the
effectiveness of anastrozole and exemestane in preventing breast
cancer in healthy postmenopausal women at high risk of developing
the disease.15,16 However, musculoskeletal symptoms have been
reported signiﬁcantly more often with AIs when compared with
tamoxifen or placebo17,18 and may account for nonadherence to
treatment, which has been reported to be as high as 25% during
the ﬁrst year of therapy.19 In a multicenter, prospective trial of
exemestane versus letrozole, 24.3% discontinued therapy because of
musculoskeletal symptoms.20 With many patients with breast cancer
taking AIs worldwide, adverse effects that can limit compliance are
of growing importance. Available data on CTS and AIs come from
clinical studies against tamoxifen in the adjuvant setting. Here, we
investigate the characteristics of CTS in women taking anastrozole
who are at high risk of developing breast cancer (IBIS-II trial),15
without the limitation of the possible confounding effect of
tamoxifen or other breast cancer treatments.
PATIENTS AND METHODS
The IBIS-II study15 is a double-blind randomized clinical trial in which
women at increased risk of breast cancer were randomly assigned to receive
oral anastrozole (1 mg/day) or matching placebo for 5 years. Details of trial
design, methods, study population, objectives, and results have been
described previously.15 All participants provided written informed consent
before trial entry. Regulatory authorities and ethics committees for all par-
ticipating centers in 18 countries approved the protocol before enrollment of
participants. The trial was performed in accordance with the Declaration of
Helsinki (1996 revision) and under the principles of Good Clinical Practice.
The IBIS-II trial is registered as an International Standard Randomized
Controlled Trial (No. ISRCTN31488319). The study has completed accrual
(n = 3,864), and follow-up is continuing for enrolled participants.
Patients were included in this analysis if CTS, as reported by the
investigator on case report forms, or CTS symptoms occurred at any time
during active treatment. CTS symptomswere deﬁned as follows: paraesthesia
in the median nerve territory described as needles, burning sensation,
tingling, heaviness, or electric impulses usually accompanied by pain
radiating to the forearm, elbow or shoulder, decrease of strength, or swelling.
This analysis was based on an intention-to-treat population. One
patient was excluded because of CTS at baseline. Analyses of potential risk
factors (treatment, age, smoking status, previous MHT use, body mass
index [BMI], and other musculoskeletal symptoms [arthralgia]) were
based on comparisons of proportions by univariate and multivariate
logistic regression (adjusted for all baseline factors). Interactions between
treatment and subgroups were based on likelihood ratio tests for an added
interaction term. Annual hazard plots were also produced. All P values are
two sided, with level of signiﬁcance at P = .05 and all CIs are at the 95%
level. All calculations were performed by use of STATA (version 12.1;
STATA, College Station, TX).
RESULTS
A total of 3,864 women were randomly assigned to receive either
anastrozole (n = 1,920) or placebo (n = 1,944). Baseline char-
acteristics are listed in Table 1 and were described in detail else-
where.15 In brief, median age was 59.5 years (interquartile range
[IQR], 55.0 to 63.5 years), and almost half of the women (47%)
had used MHT previously. The majority of the women had a BMI
of greater than 25 kg/m2 (69%) and half of the women were never-
smokers (Table 1). Patients’ characteristics were well balanced
between the two treatment arms (Table 1).
After 6.4 years (4.4 to 8.5) median follow-up, a total of 96
participants with CTS were reported (65 participants [3.4%] taking
anastrozole v 31 participants [1.6%] taking placebo; odds ratio [OR],
2.16 [1.40 to 3.33]; P, .001). Overall, median time to onset of CTS
was 1.99 years (IQR, 0.95 to 3.05 years). Figure 1 shows a histogram
of newly reported CTS according to treatment arm. Newly reported
CTS was higher in the anastrozole arm compared with placebo over
the entire course of active treatment, but the difference was par-
ticularly evident during the ﬁrst 2.5 years of treatment (Fig 1).
Women in the anastrozole arm tended to have more severe
disease (P for trend = .09). A total of 10 cases of CTS (0.3%) were
reported as severe: eight (0.4%) in the anastrozole arm and two (0.1%)
in the placebo arm (Table 1). The rate of severe CTS in the anastrozole
arm was four times higher compared with the placebo arm, but
the difference was statistically not signiﬁcant (OR, 4.06 (0.86 to 19.16);
P= .076). Amodest difference in intensity according to treatment arm
was also noted for moderate severity, with 17 participants (0.9%) in
the anastrozole arm compared with 10 participants (0.5%) in the
placebo arm (OR, 1.73 [0.79 to 3.78], P = .1). Reports of mild CTS
were similar between the two treatment groups (Table 2). Thirty-two
women (0.8%) reported bilateral CTS and similarly, 31 women
(0.8%) reported unilateral CTS (Table 2). No signiﬁcant differences
between treatment arms and laterality were observed (Table 2).
Although only 38 women (1.0%) had some sort of treatment of
CTS, the difference between the two treatment arms was statistically
signiﬁcant (OR, 2.21 [1.11 to 4.39], P = .024) (Table 2). Women
could have had more than one intervention for their CTS. Surgery
was performed signiﬁcantly more often in women in the anastrozole
arm (18 [0.9%]) compared with those in the placebo arm (six
[0.3%]) (OR, 3.06 [1.21 to 7.71]; P = .018). A further 14 women
Table 1. Baseline Demographics According to Treatment Allocation
Patient
Demographic
Anastrozole
(n = 1920)
Placebo
(n = 1944)
Age, years, mean (SD) 59.3 (5.7) 59.2 (5.7)
BMI, kg/m2
# 25 584 (30.4) 570 (29.3)
25-30 696 (36.3) 730 (37.6)
. 30 596 (31.0) 600 (30.9)
Previous MHT use 894 (46.6) 913 (47.0)
Smoking status
Never 1060 (55.2) 1130 (58.1)
Ever 825 (43.0) 785 (40.4)
NOTE: Data are presented as No. (%) unless indicated otherwise.
Abbreviations: BMI, body mass index; MHT, menopausal hormone therapy;
SD, standard deviation.
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were managed with a conservative approach (ie, cortisone injections
[n = 13] and/or wrist splint [n = 11]). There was no difference
between the two treatment arms according to conservative treatment
of CTS (Table 2).Median time to resolutionwas 1.00 year (IQR, 0.27
to 2.07 years), with no signiﬁcant differences found between
treatment arms (P = .4). Treatment was discontinued in a total of 17
women because of the onset of CTS or other adverse events (12
anastrozole v ﬁve placebo; OR, 2.44 [0.80 to 8.85]; P = .08).
Potential risk factors for developing CTS were analyzed and
are summarized in Table 3. Age, smoking, and prior MHTwere not
found to be risk factors for the development of CTS.Womenwith a
BMI between 25 and 30 kg/m2 and those with a BMI greater than
30 kg/m2 had a signiﬁcantly higher risk of developing CTS
comparedwithwomenwith a BMI of 25 kg/m2 or less (OR, 1.78 [1.07
to 2.96]; P = .02). Patients with other musculoskeletal symptoms had
a signiﬁcantly higher risk of developing CTS compared with women
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Fig 1. Histogram of newly reported carpal
tunnel syndrome (CTS) according to treat-
ment allocation.
Table 2. Severity, Characteristics, and Type of Intervention for CTS According to Treatment Allocation
Clinical Outcome
Anastrozole (n = 1920) Placebo (n = 1944)
OR (95% CI) PNo. % No. %
Total 65 3.4 31 1.6 2.16 (1.40 to 3.33) , .001
Severity
Mild 20 1.0 15 0.8 1.35 (0.69 to 2.65) .09*
Moderate 17 0.9 10 0.5 1.73 (0.79 to 3.78)
Severe 8 0.4 2 0.1 4.06 (0.86 to 19.16)
Unknown 20 — 4 —
Side
Bilateral 22 1.1 10 0.5 2.24 (1.06 to 4.75)
Unilateral 18 0.9 13 0.7 1.41 (0.69 to 2.88)
Unknown 25 1.3 8 0.4
Intervention
Yes 26 1.4 12 0.6 2.21 (1.11 to 4.39)
Type of intervention†
Surgery 18 0.9 6 0.3 3.06 (1.21 to 7.72)
Corticosteroids injection 8 0.4 5 0.3 1.62 (0.53 to 4.97)
Splint 6 0.3 5 0.3 1.22 (0.37 to 3.99)
No 39 2.0 19 1.0
Abbreviations: CTS, carpal tunnel syndrome; OR, odds ratio.
*P for trend.
†Some patients received more than one intervention.
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who did not report any musculoskeletal adverse event (3.2% v 1.6%;
OR, 2.05 [1.29 to 3.34]; P = .001).
DISCUSSION
To our knowledge, this is the ﬁrst analysis of CTS characteristics
and risk factors in healthy, postmenopausal women taking anas-
trozole in a large, randomized, placebo-controlled trial. Two
previous studies reported comparative data for anastrozole11 and
exemestane,12 but the comparator was tamoxifen. Our results show
a twofold increase in CTS for women who were randomly assigned
to anastrozole when compared with placebo.
A higher rate of CTS was observed in this retrospective
analysis of the IBIS-II trial (3.4% anastrozole and 1.6% placebo)
compared with the Arimidex, Tamoxifen, Alone or in Combi-
nation (ATAC; 2.6% anastrozole and 0.7% tamoxifen) and
Intergroup Exemestane Study (IES; 2.8% exemestane and 0.6%
tamoxifen) studies. This may be a consequence of an increased
awareness of this adverse effect by both investigators and patients
that led to a more precise reporting of symptoms. The majority of
cases of CTS in those taking anastrozole in our study were reported
early on (0 to 24months), and the incidence of newly reported CTS
decreased thereafter. A similar picture was seen in the ATAC trial,
in which most cases of CTS in those taking anastrozole were
reported within the ﬁrst 2 years, and a decline was seen thereafter.11
Overall, the incidence of CTSwith anastrozole was low (3.4%)
and fewer than two of every 1,000 women discontinued treatment
only because of the onset of CTS. In fact, the majority of CTS
reported in the anastrozole group was of mild to moderate severity,
with approximately 10% of participants reported as severe and one
out of three requiring an intervention of any kind (surgery or
corticosteroids/wrist splint). The natural evolution of CTS is
usually slow progression, but symptoms may regress sponta-
neously in approximately one-third of patients.1,21 In a large
multicenter study, 34% of patients improved without any inter-
vention, and 45% were unchanged after 1 year without any
treatment and with a short duration of symptoms being the main
favorable prognostic factor.22 In the ATAC trial,11 the rate of
surgical interventions was 13%, which was lower than our ﬁnding
of 25%. In contrast, the IES trial observed a rate of surgeries as high
as 69%.12 There is no evidence for a differential activity of these two
drugs that can explain this discrepancy.23,24 However, the higher
risk of developing CTS (OR, 5.33 vOR, 2.16 to 3.55) and the higher
rate of surgical procedures (69% v 13% to 25%) observed with
exemestane suggest that the risk and severity of CTS may be higher
with exemestane than with anastrozole. The management of CTS
was not reported uniformly because it was left to the scrutiny of
local investigators and the diagnosis is mainly clinical, so the
differences between the two classes of AIs may be the consequence
of a different approach in reporting and treating this condition.
The pathophysiology of CTS with AIs has yet to be described
fully. Studies on biochemical markers of autoimmunity and
inﬂammation show no evidence of a systemic autoimmune/
inﬂammatory process in the pathogenesis of CTS and other
musculoskeletal symptoms.25,26 Estrogen deprivation has been
hypothesized to be the main explanation for the development of
CTS,27 as well as other musculoskeletal symptoms. AIs reduce
estrogen levels in postmenopausal women, blocking the peripheral
conversion of androgenic precursors into estrogen by the aro-
matase enzyme. Estrogen is known to have antinociceptive effects,28
and Felson and Cummings29 reported increased pain-related
symptoms in women taking an AI; they argue that this may be a
consequence of a decreased threshold for pain stimuli. Other
investigators30 have found that estrogen and progesterone receptors
are expressed in the transverse carpal ligament, which forms the roof
of the carpal tunnel, and have suggested that female sex hormones
may inﬂuence the transverse carpal ligament metabolism and
directly induce CTS. Morphologic changes in the carpal tunnel
contents, such as thickening of the tendon sheaths and the
Table 3. Risk Factors at Baseline for Developing CTS According to Treatment Allocation in Univariate and Multivariate Models
Risk Factor
Women With CTS Univariate Analysis Multivariate Analysis
No. % OR (95% CI) P OR (95% CI) P
Treatment
Placebo (n = 1,944) 31 1.60 Reference Reference
Anastrozole (n = 1,920) 65 3.40 2.16 (1.40 to 3.33) , .001 2.26 (1.46 to 3.50) , .001
Age, years
# 60 (n = 2,041) 51 2.50 Reference
. 60 (n = 1,802) 45 2.50 1.00 (0.67 to 1.50) .99
Ever-smoker
No (n = 2,190) 54 2.50 Reference
Yes (n = 1,610) 41 2.60 1.03 (0.69 to 1.56) .87
Previous MHT use
No (n = 2,035) 59 2.90 Reference
Yes (n = 1,807) 37 2.10 0.70 (0.46 to 1.06) .09
BMI, kg/m2
# 25 (n = 1,154) 19 1.70 Reference Reference
25-30 (n = 1,426) 45 3.20 1.95 (1.13 to 3.35) .016 1.98 (1.15 to 3.40) .014
. 30 (n = 1,196) 31 2.60 1.59 (0.89 to 2.83) .12 1.60 (0.90 to 2.85) .11
Arthralgia
No (n = 1,715) 27 1.60 Reference Reference
Yes (n = 2,149) 69 3.20 2.07 (1.32 to 3.25) .0001 1.97 (1.25 to 3.11) .004
Abbreviations: BMI, body mass index; CTS, carpal tunnel syndrome; MHT, menopause hormone therapy OR, odds ratio.
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presence of intra-articular ﬂuid, have been reported consistently
in different studies25,26,31 and could lead to CTS increasing the
intracompartmental pressure. In our analysis, we found an
association between CTS and other musculoskeletal symptoms.
In a study on women taking adjuvant AIs compared with women
who were not, more patients with AI-related arthralgia had
ﬁndings consistent with CTS than did those without arthralgia,
suggesting that the induction of CTS by AIs may share the same
mechanisms of other musculoskeletal symptoms.26
Our study has some limitations. Data on the severity and date
of resolution of CTS were missing for several women, even after
speciﬁc inquiries. Diagnosis, management and reporting of CTS
were left to local investigators and were therefore heterogeneous,
and full clinical details were not captured. Nevertheless, this should
not bias our comparative analysis because the study was double
blinded, so neither the investigator nor the patient was aware of the
treatment. Median follow-up is more than 6 years, and because
most cases occur early in the treatment period, we will have
captured almost all of the treatment-related cases.
In summary, the use of anastrozole was associated with a
higher incidence of CTS, with an excess incidence of 1.8% after
treatment completion. Most CTS cases were of mild to moderate
intensity, and only 0.8% of women taking anastrozole required
surgical intervention. Further investigations are warranted that
examine the risk factors for CTS, the musculoskeletal symptoms
after AI treatment, and the ways in which CTS can be avoided or
ameliorated.
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